Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ludlow Alt. Energy Index
http://www.ludlowenergy.com/indices/historic/index.html
GRSR next WWAT
keep an eye on GiraSolar (GRSR), as it could have a strong run like WWAt has been having. About to file US GAAP 2006 numbers, and expecting $60 million in revs.
Check these numbers
2006 Revenues = $60 mill
2007 Revenues (projected) = $80 mill
Shares Outstanding = 35 mill
Market Cap = $10 mill
--> $10 mill market cap on solar company doing $60 mill in sales
--> trading 'below' 1 x sales
--> most solar stocks trade at 10 x sales
* worth grabbing some down in the .30's
may be heading back up this week...
If CBPC can break .10 we could slowly creep back up above .10 and possibly test .14 in the coming week or so. Like to see the volume break 200k to confirm.
CBPC - heading up (.087 x .092)
Break above .10 and CBPC is off to the races.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cbpc&sid=0&o_symb=cbpc&f...
Intersolar photos....
not of GRSR but of the event in general. Will email GRSR to see if they have any photos of their event there. anyways, still interesting pics.
http://www.intersolar.de/17+M52087573ab0.html
cant fire Klamka....
he's the CEO and the one who caused all these problems.
It's all in their 10Q...
They have a convertiable note here, but with this volume it looks like they may be working their through it pretty quickly.
Lot of warrants on the stock, 10Q spells it out.
2 on bid at .10....
they may be ready to let this move above .11 and new high of the day. Would be a big positive if volume broke above 1.1 million today.
CBPC - .105 x .11 (look at chart)
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cbpc&sid=0&o_symb=cbpc&f...
heading back up...
to test days high
gonna ripe through .10 at the open...
maybe pause at .11, and if we get follow through buying from traders coming in we'll head hihger. Could be an interesting week.
CBPC has Influenza vaccine...
main thing that makes CBPC different from other 'bird flu' plays is they already have a Influenza vaccine. All they would have to do is roll in the new strain of any H5N1 virus into their current influenza vaccine, and just begin producing, just like they do every year with the common flu starin each year.
problem with bird flu is if/when it finally breaks out we wont have the actual strain, but CBPC would be a big if not #1 player in China if an outbreak occurs. That's the risk rewatd here.
Watch China news for bird flu
CBPC way undervalued...
company had a note which is being work through now, but im impressed by the people on the board. Real people, real scientists, real products, not a research company.
Looking for bigger name joint ventures going forward. Doing one with japan's largest vaccine distributor.
Just needs to work through the note...
once I believe this note is done we'll see this head back over .25 at least. hopefully dilution isnt massive, but the volume is looking decent and we could be through it soon.
Im impressed by the people on the company board....real people, real scientists, real products, not research.
id look forward to more big joint ventures with big global names.
CBPC - .075 x .077 (news)
- launches new anti-viral drug
- joint venture with Japan's largest biopharm company
- projecting $10 to $13 mill in revenue
- largest 'private' vaccine distributor in China
- close contacts with china's CDC
- avian H5N1 research
a steal under .10...real company, real people
UTVG upgraded from 1.80 to 3.25
Ludlow China issued an upgrade on UTVG Tuesday from 1.80 to 3.25, with a B - rating.
Chat is looking sharp, and looks like it may try for a new run at the high, weeeee.
- http://www.ludlowchina.com/reports/utvg.htm
GRSR possed to break 50 day MA
Last time GRSR broke the 50 day MA on the upside was in mid-Dec 2006. the 50 day is a major resistance line for the stock, and with the 50 day = 0.39, and 10K due out any moment, we could be set to spike above that and head higher.
Watch .38 to .39 as a key price resistance.
http://stockcharts.com/h-sc/ui?s=GRSR&p=D&yr=0&mn=11&dy=0&id=p63741409600
CBPC - .075 x .077 (movin on news)
launches new anti-viral drug....real deal. Check it out.
Intersolar 2007 starts today
GiraSolar Will Exhibit at the World's Major Solar Event of 2007, Intersolar 2007, Occurring June 21st Through June 23rd in Freiburg, Germany.
CBPC launches new anti-viral drug
China Biopharma Reaches Agreement to Introduce a New Antiviral Drug
PRINCETON, N.J., June 21, 2007 /PRNewswire-FirstCall via COMTEX/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced that it has reached agreements with Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") to introduce a new antiviral medicine into the overseas market including the United States and European countries. This all-natural medicine has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV by 90% only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33.
Human papillomavirus infection is common across all races and socioeconomic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression. Consequently, there is an urgent medical need unmet for the development of safe and effective therapies for HPV-associated diseases. According to a research by Decision Resources, the market for HPV treatment is expected to grow from $135 million in 2002 to $1.4 billion (AEUR1.08 billion) in 2012.
China Biopharma will utilize its presence in both US and China to initially introduce this all-natural external-use medicine. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and USA so as to obtain approval necessary for selling this medicine as an over-the-counter drug. The company believes this medicine would bring in significant revenue and profit in the near future once it is successfully introduced into the market.
About China Biopharma, Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.
Load Up! WWEI related news
China overtakes U.S. as top CO2 emitter
BEIJING - China has overtaken the United States as the world's top producer of carbon dioxide emissions — the biggest man-made contributor to global warming — based on the latest widely accepted energy consumption data, a Dutch research group says.
http://news.yahoo.com/s/ap/20070620/ap_on_re_as/china_climate_change
WWEI is one of the few clean energy/china stock plays I know, next to all those Chinese solar stocks, that trade at like $30 to $70. Great cheap clean energy/China play. Word will leak out and this will run, IMO.
market may be testing for sellers...
market might be holding still to see if there is still any sellers out there, and if they dont get hit at end of today you might see them begin to bring the bid and jump on the offer.
10K thing is such a mess, but said we'd get it this month....could be anytime now. (geez, been saying that for the longest, lol)
Ludlow Energy Index
tracks a basket of alternative energy stocks...gives you a good idea on how institutional money is flowing in the sector intraday.
http://www.ludlowenergy.com/indices/historic/
Ludlow report on them
incase you hadnt seen from a few months back.
- http://www.ludlowchina.com/reports/
B- doesnt seem bad to me...
Their site has information on how they rate these things. Been watching CHND since late last year, they seemed to put this deal together the right way.
http://www.ludlowchina.com/reports/about.html
CBPC - .073 x .074 (upgraded)
check out their recent PR's....real deal company.
CBPC - .0724 x .0725 (upgraded)
Ludlow China Upgrades China Biopharma, Inc.
Monday June 18, 8:00 am ET
PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Ludlow China upgrades China Biopharma, Inc. (OTC Bulletin Board: CBPC - News) from a C to B- rating based on a recent guidance for fiscal year 2007 issued by the company. On June 13, 2007, the company issued revenue guidance for fiscal year 2007 of between $10 million to $13 million, with projected positive net income. Based on a price to sales (P/S) ratio of just 3 times sales that would give CBPC a valuation of $30 to $39 million. With around 90 million shares outstanding, that would give CBPC a potential target of around $0.30 to $0.40 a share.
INVESTMENT HIGHLIGHTS
-- Market Growth - the market in China for flu vaccinations has grown from
3.9 million doses in 2000 to 22.3 million doses in 2005, or 30% year
over year.
-- Distribution Network - the company has the largest independent vaccine
distribution network covering 268 cities in China.
-- Strategic Alliances - the company retains a close relationship with the
Chinese Center of Disease Control (CDC), providing local CDC
vaccinations, and providing their high-capacity production facility for
any potential epidemics within China.
-- Product Pipeline - in addition to marketing vaccines for Influenza,
Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the
company is also conducting research such new products to cover
allergies and avian bird flu.
-- Revenue Projection - management anticipates generating $10 to $13
million in annual revenues and positive net income for fiscal year
2007.
-- Management Experience - the company retains some of the top scientists
within the human vaccine fields in China, and has had a number of years
experience running a public company.
For a link to the full investment opinion, and risks associated with this company visit - http://www.ludlowchina.com/reports/cbpc.htm
GRSR vs. WWAT
Seen that WWAT has been rockin, and so did a quick camparison between both.
For 2006
Revenues
WWAT = $17.1 million
GRSR = $60 million
Gross Profit
WWAT = $2.7 million
GRSR = $1.1 million
Net Loss
WWAT = ($11.4 million)
GRSR = ($360k)
EPS
WWAT = ($0.08)
GRSR = ($0.00)
Shares Outstanding
WWAT = 135 million
GRSR = 35 million
Share Price
WWAT = 1.10
GRSR = 0.37
* We're closer to profit then WWAT.
could test the 50 day MA
GRSR hasnt been above its 50 day MA since Feb 2007, and just has to break above .39
http://stockcharts.com/h-sc/ui?s=GRSR&p=D&yr=0&mn=6&dy=0&id=p33443978555
Also expecting 10K anytime now. Come auditers....file it!
risk note
Risk Note: This projected formula is based on 90 million shares outstanding, and depending on future dilution these targets can change. The company currently has a convertible note outstanding, and thus has some issues to work through before any determined move upward. Another risk factor would be the company's inability to meet revenue targets going forward.
Ludlow China is recommending CBPC as a 'speculative high risk' equity.
republicans blocking energy bill
WASHINGTON - Three powerful lobbying forces — automakers, electric utilities and the coal industry — are confounding Democrats' efforts to forge a less-polluting energy policy.
Disputes over automobile fuel economy, use of coal as a motor fuel, and requirements for utilities to use more wind or biomass to generate electricity have threatened to stall energy legislation in both the Senate and House.
An intense GOP fight against the proposal has been waged largely at the behest of two of the country's biggest coal-burning electricity producers — the Atlanta-based Southern Company and the Tennessee Valley Authority.
http://news.yahoo.com/s/ap/20070618/ap_on_go_co/congress_energy;_ylt=AszGzQEDmLbrkXmOAJLcd6qs0NUE
surprised not more around...
nice volume over the past few trading days, kind of surprised we dont see more people or at least flippers posting about. Bidded some down here, but would like to see it move above .10 before any real commitment. Wait until the convertable note gets done.
Ludlow China - CHCG to $10...
Ludlow China Upgrades Coverage on China 3C Group, 12 Month Target of $10.00 a Share, and A- Rating
Last Updated: May 16, 2007
http://www.ludlowchina.com/reports/chcg.htm
They may be too low IMO. I'm thinking in 12 months you could be looking at a $15 to possibly even $20 stock, but $15 more likely.
dont know about .40, but could be a play up to .15 or .20 Really all depends on how much of this note they have to go through before it moves up. See they mentioned it as a risk factor.
Ludlow China rates CHND B-
http://www.ludlowchina.com/reports/index.html
avian bird flu
-- Product Pipeline - in addition to marketing vaccines for Influenza,Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the company is also conducting research such new products to cover allergies and avian bird flu.
------------
HANOI, June 18 (Reuters) - Bird flu, which has killed one person since it re-emerged in Vietnam in early May, has flared up on several farms in a northern province despite efforts by the government to ...
http://news.search.yahoo.com/news/search?p=bird+flu&c=
CBPC moving on Upgarde ++++++
Ludlow China Upgrades China Biopharma, Inc.
Monday June 18, 8:00 am ET
PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Ludlow China upgrades China Biopharma, Inc. (OTC Bulletin Board: CBPC - News) from a C to B- rating based on a recent guidance for fiscal year 2007 issued by the company. On June 13, 2007, the company issued revenue guidance for fiscal year 2007 of between $10 million to $13 million, with projected positive net income. Based on a price to sales (P/S) ratio of just 3 times sales that would give CBPC a valuation of $30 to $39 million. With around 90 million shares outstanding, that would give CBPC a potential target of around $0.30 to $0.40 a share.
http://finance.yahoo.com/q?s=CBPC.OB